ArticleJournal of the Chinese Medical Association : JCMA2025
Clinical characteristics and prognostic factors in patients with stool cytomegalovirus positivity.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical association between cytomegalovirus (CMV) DNA detection in stool samples and patient outcomes remains underexplored. This study aimed to assess prognostic factors and viral kinetics in patients with positive stool CMV polymerase chain reaction (PCR).
methodsThis retrospective cohort study included adult patients with positive stool CMV-PCR results at Taipei Veterans General Hospital (2016-2021). Clinical data, plasma, and stool viral loads (VLs) were analyzed. Receiver operating characteristic (ROC) curves and area under the curve (AUC) evaluated 30-day mortality prediction, with optimal cutoffs maximizing sensitivity and specificity. Kaplan-Meier survival analyses and Cox proportional hazards models identified predictors of 30-day mortality.
resultsA total of 114 patients (mean age: 64.0 years, 64% male) were included. The median stool CMV VL was 629 copies/mL (interquartile range [IQR]: 263-7949). Plasma CMV DNA was detected in 76% with a median VL of 341 copies/mL (IQR: 10-1771). Stool and plasma VLs showed moderate correlation ( ρ = 0.38, p < 0.0001). ROC analysis identified cutoffs for predicting 30-day mortality: stool 9654 copies/mL (AUC = 0.54; sensitivity 42%; specificity 81%) and plasma 1738 copies/mL (AUC = 0.60; sensitivity 47%; specificity 70%). In multivariate Cox analysis, stool CMV VL >9,654 copies/mL (adjusted hazard ratio: [HR] 2.69, 95% confidence interval [CI]: 1.06-6.84; p = 0.04) and plasma CMV VL >1738 copies/mL (adjusted HR: 2.66, 95% CI: 1.14-6.17; p = 0.02) were independent predictors of 30-day mortality. Septic shock and steroid use were also associated with increased mortality, whereas antiviral therapy ≥7 days was independently protective (adjusted HR: 0.26, 95% CI: 0.10-0.64; p = 0.003).
conclusionStool and plasma CMV VLs, antiviral treatment duration, and host factors such as immune status may influence outcomes in patients with intestinal CMV reactivation. Larger studies are needed to validate optimal VL thresholds for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.